CatalYm has announced the closure of an oversubscribed EUR50 million Series C financing round that was co-led by new investors, Brandon Capital and Jeito Capital, with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, BioGeneration Ventures and Coparion. …
Australian venture capital fund joins partners in backing new immunotherapy
November 24, 2022 Latest NewsAustralian Biotech
Latest Video
New Stories
-
Mark Butler: Patients waiting too long and 'as the Health Minister, of course, I am sorry for that'
March 24, 2025 - - Latest News -
Call for safety net change with half a million Australians missing out on cheaper medicines
March 24, 2025 - - Latest News -
Nanotechnology could improve odds in treating aggressive breast cancers
March 24, 2025 - - Latest News -
Industry pushes back on conspiracy theories, highlighting the Government's own comments
March 22, 2025 - - Latest News -
Medicines Australia announces appointment of new board chair
March 20, 2025 - - Latest News -
The 'Week in Review Dispatched' Podcast - 21 March
March 20, 2025 - - Podcast -
New NZ approval clears the way for expanded access to cystic fibrosis therapy
March 20, 2025 - - Latest News